TIBSOVO is nonmyelosuppressive, with a well-characterized safety profile1

Adverse reactions in ≥10% in patients with R/R MDS

 
TIBSOVO (500 mg daily)
(N=19)
Body system
Adverse reaction
All grades Grade 3 or 4
Musculoskeletal and connective tissue disorders
Arthralgiaa 42% 16%
Myalgiab 26% 0%
General disorders and administration site conditions
Fatiguec 37% 11%
Respiratory, thoracic, and mediastinal disorders
Cough 32% 0%
Dyspnead 21% 0%
Gastrointestinal disorders
Diarrhea 32% 0%
Mucositise 26% 5%
Constipation 16% 0%
Nausea 16% 0%
Metabolism and nutrition disorders
Decreased appetite 26% 0%
Skin and subcutaneous tissue disorders
Pruritus 26% 0%
Rashf 26% 0%
Blood system and lymphatic system disorders
Leukocytosisg 16% 5%
Differentiation syndrome 11% 0%
Nervous system disorders
Headache 16% 0%
Vascular disorders
Hypertension 16% 16%
Investigations
Electrocardiogram QT prolonged 11% 0%

aGrouped term includes arthralgia, back pain, pain in extremity, flank pain, joint swelling, and neck pain.

bGrouped term includes myalgia, muscle spasms, muscle discomfort, and musculoskeletal chest pain.

cGrouped term includes fatigue and asthenia.

dGrouped term includes dyspnea and dyspnea exertional.

eGrouped term includes oropharyngeal pain, gingivitis, mouth ulceration, stomatitis.

fGrouped term includes rash, catheter site erythema, and urticaria.

gGrouped term includes leukocytosis, hyperleukocytosis, and white blood cell count increased.

  • The majority of adverse reactions with TIBSOVO were Grade 1 or 21
  • Serious adverse reactions in ≥5% of patients included differentiation syndrome (11%), fatigue (5%), and rash (5%)1
  • All patients with relapsed or refractory MDS who experienced differentiation syndrome recovered after treatment or after dose interruption of TIBSOVO

MDS, myelodysplastic syndromes; mIDH1, mutated IDH1; QTc, corrected QT interval; R/R, relapsed or refractory.

Laboratory abnormalities1

Select laboratory abnormalities (≥15%) that worsened from baseline in patients with R/R MDSa

 
TIBSOVO (500 mg daily)
(N=19)
Parameter
All grades Grade 3 or 4
Creatinine increased 95% 5%
Hemoglobin decreased 42% 32%
Albumin decreased 37% 0%
Aspartate aminotransferase increased 37% 5%
Sodium decreased 32% 5%
Phosphate decreased 26% 5%
Alanine aminotransferase increased 21% 5%
Bilirubin increased 21% 0%
Magnesium decreased 21% 0%
Alkaline phosphatase increased 16% 0%
Potassium increased 16% 0%

aLaboratory abnormality was defined as new or worsened by at least one grade from baseline or if baseline was unknown.

Dose modifications1

Dose discontinuations, interruptions, and reductions

  • Permanent discontinuation of TIBSOVO due to an adverse reaction occurred in one (5%) patient. The adverse reaction that resulted in permanent discontinuation of TIBSOVO was fatigue
  • Adverse reactions leading to dose interruption of TIBSOVO occurred in 16% of patients. Adverse reactions that required dose interruption in ≥5% were differentiation syndrome, leukocytosis, and rash
  • Dose reductions of TIBSOVO due to an adverse reaction occurred in 16% of patients. Adverse reactions that required a dose reduction in ≥5% included differentiation syndrome, fatigue, and rash

Warnings and precautions

Differentiation syndrome in MDS

  • Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal
  • Symptoms of differentiation syndrome in patients treated with TIBSOVO included noninfectious leukocytosis, peripheral edema, pyrexia, dyspnea, pleural effusion, hypotension, hypoxia, pulmonary edema, pneumonitis, pericardial effusion, rash, fluid overload, tumor lysis syndrome, and creatinine increased
  • If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement
  • If concomitant noninfectious leukocytosis is observed, initiate treatment with hydroxyurea or leukapheresis, as clinically indicated
  • Taper corticosteroids and hydroxyurea after resolution of symptoms, and administer corticosteroids for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid and/or hydroxyurea treatment
  • If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, interrupt TIBSOVO until signs and symptoms are no longer severe

QTc interval prolongation

  • Patients treated with TIBSOVO can develop QT (QTc) prolongation and ventricular arrhythmias
  • Concomitant use of TIBSOVO with drugs known to prolong the QTc interval (eg, anti-arrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes
  • In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary
  • Interrupt TIBSOVO if QTc increases to greater than 480 msec and less than 500 msec. Interrupt and reduce TIBSOVO if QTc increases to greater than 500 msec. Permanently discontinue TIBSOVO in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia

Guillain-Barré syndrome

  • Guillain-Barré syndrome can develop in patients treated with TIBSOVO
  • Monitor patients taking TIBSOVO for onset of new signs or symptoms of motor and/or sensory neuropathy such as unilateral or bilateral weakness, sensory alterations, paresthesias, or difficulty breathing. Permanently discontinue TIBSOVO in patients who are diagnosed with Guillain-Barré syndrome

Reference: 1. Tibsovo. Package insert. Servier Pharmaceuticals LLC; 2023.

 

Indication

TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME IN MDS
Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

WARNINGS AND PRECAUTIONS

Differentiation Syndrome in MDS: Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal. Symptoms of differentiation syndrome in patients treated with TIBSOVO included noninfectious leukocytosis, peripheral edema, pyrexia, dyspnea, pleural effusion, hypotension, hypoxia, pulmonary edema, pneumonitis, pericardial effusion, rash, fluid overload, tumor lysis syndrome, and creatinine increased.

If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement. If concomitant noninfectious leukocytosis is observed, initiate treatment with hydroxyurea or leukapheresis, as clinically indicated. Taper corticosteroids and hydroxyurea after resolution of symptoms and administer corticosteroids for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid and/or hydroxyurea treatment. If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, interrupt TIBSOVO until signs and symptoms are no longer severe.

QTc Interval Prolongation: Patients treated with TIBSOVO can develop QT (QTc) prolongation and ventricular arrhythmias. Concomitant use of TIBSOVO with drugs known to prolong the QTc interval (e.g., anti-arrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary.

Interrupt TIBSOVO if QTc increases to greater than 480 msec and less than 500 msec. Interrupt and reduce TIBSOVO if QTc increases to greater than 500 msec. Permanently discontinue TIBSOVO in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.

Guillain-Barré Syndrome: Guillain-Barré syndrome can develop in patients treated with TIBSOVO. Monitor patients taking TIBSOVO for onset of new signs or symptoms of motor and/or sensory neuropathy such as unilateral or bilateral weakness, sensory alterations, paresthesias, or difficulty breathing. Permanently discontinue TIBSOVO in patients who are diagnosed with Guillain-Barré syndrome.

ADVERSE REACTIONS

The most common adverse reactions including laboratory abnormalities (≥25%) in patients with relapsed or refractory MDS are creatinine increased, hemoglobin decreased, arthralgia, albumin decreased, aspartate aminotransferase increased, fatigue, diarrhea, cough, sodium decreased, mucositis, decreased appetite, myalgia, phosphate decreased, pruritus, and rash.

DRUG INTERACTIONS

Strong or Moderate CYP3A4 Inhibitors: Reduce TIBSOVO dose with strong CYP3A4 inhibitors. Monitor patients for increased risk of QTc interval prolongation.

Strong CYP3A4 Inducers: Avoid concomitant use with TIBSOVO.

Sensitive CYP3A4 Substrates: Avoid concomitant use with TIBSOVO.

QTc Prolonging Drugs: Avoid concomitant use with TIBSOVO. If co-administration is unavoidable, monitor patients for increased risk of QTc interval prolongation.

LACTATION

Advise women not to breastfeed.

Please see Full Prescribing Information, including BOXED WARNING for MDS patients.

Last update: August 2026


Information on this website is reviewed through established medical, legal, and regulatory processes to support accurate, balanced, and label-consistent communication about TIBSOVO.

 

INDICATION

TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Indication & Important Safety Information

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME IN MDS

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.